Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP948033.RAmTv6pS9Kl9qc6taJkrHv1YZbxDPmgKuwxRmB0hoRAc8130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP948033.RAmTv6pS9Kl9qc6taJkrHv1YZbxDPmgKuwxRmB0hoRAc8130_assertion type Assertion NP948033.RAmTv6pS9Kl9qc6taJkrHv1YZbxDPmgKuwxRmB0hoRAc8130_head.
- NP948033.RAmTv6pS9Kl9qc6taJkrHv1YZbxDPmgKuwxRmB0hoRAc8130_assertion description "[They had received VP16, methotrexate, 6MP/6TG, L-asparaginase, daunorubicin, cytarabine, and VM26 more often, likely attributed to the high frequency of AL as their primary disease.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP948033.RAmTv6pS9Kl9qc6taJkrHv1YZbxDPmgKuwxRmB0hoRAc8130_provenance.
- NP948033.RAmTv6pS9Kl9qc6taJkrHv1YZbxDPmgKuwxRmB0hoRAc8130_assertion evidence source_evidence_literature NP948033.RAmTv6pS9Kl9qc6taJkrHv1YZbxDPmgKuwxRmB0hoRAc8130_provenance.
- NP948033.RAmTv6pS9Kl9qc6taJkrHv1YZbxDPmgKuwxRmB0hoRAc8130_assertion SIO_000772 11921271 NP948033.RAmTv6pS9Kl9qc6taJkrHv1YZbxDPmgKuwxRmB0hoRAc8130_provenance.
- NP948033.RAmTv6pS9Kl9qc6taJkrHv1YZbxDPmgKuwxRmB0hoRAc8130_assertion wasDerivedFrom befree-20150227 NP948033.RAmTv6pS9Kl9qc6taJkrHv1YZbxDPmgKuwxRmB0hoRAc8130_provenance.
- NP948033.RAmTv6pS9Kl9qc6taJkrHv1YZbxDPmgKuwxRmB0hoRAc8130_assertion wasGeneratedBy ECO_0000203 NP948033.RAmTv6pS9Kl9qc6taJkrHv1YZbxDPmgKuwxRmB0hoRAc8130_provenance.